In this study, authors have used responses to questionnaires included in the CS21 degarelix trial and published mapping algorithms to address the paucity of evidence for health–related quality of life (HRQL) for patients with advanced hormone–dependent prostate cancer treated with degarelix.

PSA progression status and the incidence of treatment– and disease–related adverse events result in significant decrements to patient HRQL. By slowing PSA progression, degarelix may improve patient utility and the HRQL burden.

READ FULL ARTICLE Curated publisher From Mdlinx